Efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma: a real-world study
In the real world, selinexor-based regimens demonstrate good efficacy and controllable safety as first-line treatments for elderly patients with DLBCL.
Authors
- Peng Sun (ORCID: https://orcid.org/0000-0003-3811-0371)
- Zhiming Li (ORCID: https://orcid.org/0000-0002-8170-5621)
- Tingting Chen (ORCID: https://orcid.org/0000-0002-8067-0287)
- Jing Li (ORCID: https://orcid.org/0000-0002-4289-4829)
- Yu Wang (ORCID: https://orcid.org/0000-0003-2265-3742)
- Shan Liu (ORCID: https://orcid.org/0009-0008-6981-9731)
- Shulan Wang (ORCID: https://orcid.org/0000-0002-1413-8022)
- Hang Yang
- Jiajia Huang (ORCID: https://orcid.org/0000-0002-9498-0542)
- Jingjing Ge (ORCID: https://orcid.org/0000-0002-8609-3804)
- Xiaohua He (ORCID: https://orcid.org/0000-0003-3627-1219)
- Jianghua Cao
Institutions
- Sun Yat-sen University (CN)
- Southern University of Science and Technology (CN)
- Guangdong Academy of Medical Sciences (CN)
- Sun Yat-sen University Cancer Center (CN)
- Shenzhen Second People's Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1186/s12885-025-14295-6
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- National Natural Science Foundation of China
- Sun Yat-sen University
- Sun Yat-sen University Cancer Center